4.7 Article

White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 40, Issue 13, Pages 3027-3035

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2015.158

Keywords

-

Funding

  1. NIH [T32-MH19986, R25-MH060473, R01 MH37869, K02-MH064190, K23-MH086686, K23-MH64678, K01-MH01684, P30 MH52247, P50 AG05133-18S2]
  2. University of Pittsburgh Clinical Scientist Training Program (CSTP)
  3. Clinical and Translational Science Institute [UL1 TL1TR000005]
  4. NIMH Medical Student Research Fellowship
  5. Bristol Meyers Squibb
  6. Forrest Labs
  7. Lily
  8. Pfizer

Ask authors/readers for more resources

White matter hyperintensities (WMHs) have been shown to be associated with the development of late-life depression (LLD) and eventual treatment outcomes. This study sought to investigate longitudinal WMH changes in patients with LLD during a 12-week antidepressant treatment course. Forty-seven depressed elderly patients were included in this analysis. All depressed subjects started pharmacological treatment for depression shortly after a baseline magnetic resonance imaging (MRI) scan. At 12 weeks, patients underwent a follow-up MRI scan, and were categorized as either treatment remitters (n = 23) or non-remitters (n = 24). Among all patients, there was as a significant increase in WMHs over 12 weeks (t(46) = 2.36, P = 0.02). When patients were stratified by remission status, non-remitters demonstrated a significant increase in WMHs (t(23) = 2.17, P = 0.04), but this was not observed in remitters (t(22) = 1.09, P = 0.29). Other markers of brain integrity were also investigated including whole brain gray matter volume, hippocampal volume, and fractional anisotropy. No significant differences were observed in any of these markers during treatment, including when patients were stratified based on remission status. These results add to existing literature showing the association between WMH accumulation and LLD treatment outcomes. Moreover, this is the first study to demonstrate similar findings over a short interval (ie 12 weeks), which corresponds to the typical length of an antidepressant trial. These findings serve to highlight the acute interplay of cerebrovascular ischemic disease and LLD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available